Red Arrow Therapeutics Inc., a Boston, MA-based developer of pH-sensing nanomedicine drug delivery technologies, closed a $4.5M Seed Extension round.
Participants of this round were:
- Beyond Next Ventures Inc.
- The University of Tokyo Edge Capital Partners Co., Ltd.
- Keio Innovation Initiative, Inc.
- OSAKA University Venture Capital Co., Ltd.
The Seed extension round will allow the company to obtain key preclinical data on safety and efficacy of their lead compound, IL-12-loaded nanopolymeric micelles. The funding will also enable manufacturing initiation in collaboration with external partners.
This boosts the accumulative funding raised by Red Arrow Therapeutics to nearly $5.5M, along with previous funding from The University of Tokyo Edge Capital Partners Co., Ltd., University of California, Berkeley’s accelerator SkyDeck , and other non-dilutive funding.
Emerged from the University of Tokyo’s Cabral Lab in 2021, Red Arrow Therapeutics develops pH-sensing nanomedicine drug delivery technologies for multiple therapeutic areas such as oncology.
Founders included Takuya Miyazaki, Ph.D. , Horacio Cabral, Ph.D., and Rika Tajima, MPH.
The company also has an office in Tokyo.
FinSMEs
23/04/2024